Navigation Links
MiMedx Files Its Initial Investigational New Drug Application
Date:7/23/2014

MARIETTA, Ga., July 23, 2014 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, processor and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it has filed its initial Investigational New Drug ("IND") application with the Food and Drug Administration ("FDA").  

The IND submission, which was filed yesterday, July 22, 2014, is the Company's initial submission for certain indications of its micronized allografts towards targeted Biologics License Applications ("BLAs").  As communicated in the Company's December 4, 2013, press release, this IND filing is the first major milestone in the process, which is expected to culminate in at least two separate BLAs for certain indications of the Company's micronized allografts.

Parker H. "Pete" Petit, Chairman and CEO, stated, "I am very pleased that we were able to complete this initial IND submission to the FDA on an accelerated schedule.  This first step in the BLA regulatory pathway for certain of our micronized allografts is strategically important as a guidepost for our future pursuit of other amniotic tissue products that may need approval via the FDA's BLA process. We are committed to efficiently satisfying all facets of this process and successfully transitioning our micronized products from Section 361 HCT/Ps to licensed biologics."

About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas.  Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 250,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the effect of the filing of the IND application and the Company's ability to transition its micronized products to licensed biologics or pursue BLAs for future products.  These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the IND application will not be granted, that the associated clinical trials will not be successful, that the Company will not apply for or be granted one or more BLAs, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2013.  By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

                                                                                                                


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
2. MiMedx Group to Present at the 6th Annual OneMedForum
3. MiMedx Announces 2012 Results
4. MiMedx Group, Inc. Announces Release Date for 2013 Second Quarter Results
5. MiMedx Addresses FDA Untitled Letter And Reiterates 2013 And 2014 Guidance
6. MiMedx Announces Conference Call To Discuss FDA "Untitled Letter" And Reiterate Guidance
7. MiMedx to meet with FDA in Mid-October
8. Seven Poster Abstracts Highlight MiMedx Allografts at the 10th Annual Desert Foot Conference
9. MiMedx Announces Next Steps After Discussions With The FDA
10. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
11. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 06, 2016 , ... Experimentation involving human stem cells (HSCs) ... to its potential for revolutionizing human disease treatment. There are multiple HSC platforms ... cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but what ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... TopConsumerReviews.com recently ... Mobility Scooters . , Mobility Scooters give freedom to people who need help ... Still others may be facing a long period of rehabilitation after an illness or ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
Breaking Medicine News(10 mins):